Current and Emerging DMARDs for the Treatment of Rheumatoid Arthritis.

Open Access Rheumatol

Organización Medica de Investigación, Buenos Aires, Argentina.

Published: June 2021

Rheumatoid arthritis (RA) is the most prevalent form of inflammatory arthritis. It is a profoundly serious and severe disease that if it goes untreated could have severe consequences to the joints and health of the patient who carries this diagnosis. The treatment of RA has dramatically changed since the year 2000, with the discovery of the TNFis, then other biologics, and finally the JAKi. All these new medications with or without methotrexate in combination, tight control and treat to target have produced a revolution in the outcome of this disease. We reviewed and summarized the treatment options, and the most significant papers for each one of these new drugs. The reader could have a full picture with all the references of the recent publications. We also updated the biosimilar situation in RA, as well as the new drugs that will be coming to the market in the next 5 years.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8179789PMC
http://dx.doi.org/10.2147/OARRR.S282627DOI Listing

Publication Analysis

Top Keywords

rheumatoid arthritis
8
current emerging
4
emerging dmards
4
dmards treatment
4
treatment rheumatoid
4
arthritis rheumatoid
4
arthritis prevalent
4
prevalent form
4
form inflammatory
4
inflammatory arthritis
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!